Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aggressive Treatment More Effective for Nasopharyngeal Cancer

09.08.2004


Radiation therapy (RT) has been the most important treatment modality with curative potential in treating patients with cancer of the nasopharynx, the part of the pharynx that lies above the soft palate. This is due to several factors: (1) undifferentiated carcinoma, or tumour cells with no resemblance at all to normal glandular or surface lining cells, is quite radiosensitive and is more common than squamous cell carcinoma; (2) more than two-thirds of the patients present with cervical lymph node metastases at time of diagnosis; (3) about half of the patients present with bilateral cervical metastases; (4) retropharyngeal lymph node, which is difficult to remove surgically, is frequently involved at rather earlier stages.

Local control and survival rates have been improved by increasing the radiation dose since 1950’s, and favorable 10-year survival rates ranging from 65 to 77 percent were achievable in patients with early stage disease by high dose radiation therapy. However, the long-term survival rates in those with high T or N stages are not satisfactory because of either poor local control or frequent distant metastases. The addition of systemic chemotherapy to high dose RT has been widely tried in an effort to overcome these limitations.

Three sequences of combining chemotherapy RT have been tried: chemotherapy before surgery followed by radiation therapy; adjuvant chemotherapy after RT; and concurrent radiochemotherapy. Based on several phase III trials, positive role of chemotherapy that was added to RT in locally advanced nasopharynx cancer was proved, and the concurrent fashion was regarded, if not conclusive, as the most effective strategy.



High dose radiation therapy with concurrent systemic chemotherapy in the patients with locally advanced nasopharynx cancer has been the treatment policy at a South Korean medical institute since 1995. Staff members at the institute set out to analyze and report the failure patterns and survival outcomes associated with this treatment. Their findings can be found in the research effort, “High Dose Radiation Therapy Concurrent with Chemotherapy in Locally Advanced Nasopharynx Cancer,” authored by Min Kyu Kang, MD, Yong Chan Ahn, MD, Won Park, MD, Keunchil Park, MD, Chung-Hwan Baek, MD, Young Ik Son, MD, Jeong Eun Lee, MD, Young Je Park, MD, Hee Rim Nam, MD, Kyoung Ju Kim, MD, Do Hoon Lim, MD, and Seung Jae Huh, MD, all from the Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Their findings are to be presented at the 6th International Conference on Head and Neck Cancer being held August 7-11, 2004, at the Wardman Park Marriott, in Washington, D.C.

Methodology: Sixty patients with nasopharynx cancer received high dose curative radiation therapy at the authors’ institute from April, 1995, to May 2001. Excluding eight patients who received high dose RT alone, 52 were given high dose radiation therapy with concurrent systemic chemotherapy. To be eligible for this treatment protocol, patients needed to (1) have locally advanced stage disease, (2) be in ECOG performance score from 0 to 2, (3) have no major medical illness that would hinder this rather aggressive approach, (4) have adequate hematopoietic, hepatic, and renal reserves, (5) have no past history of malignancy other the current diagnosis, and (6) consent to this protocol.

The treatment consisted of:

Radiation therapy: RT was administered using 4 MV or 6 MV x-rays generated from a linear accelerator. Conventional fractionation schedule to deliver five daily fraction of 1.8 Gy per week was used. Serial shrinking field technique was applied to all patients, and the median doses to the primary lesions and grossly enlarged lymph nodes, were 72 (64~80) Gy and 59.4 (37.8~72) Gy. The elective lymphatic irradiation volume and its radiation dose were individually determined based on the initial clinical findings, and the median elective lymphatic irradiation dose was 45 (36~45) Gy.

Chemotherapy: Two types of chemotherapy regimen and schedule were used. Eight patients received Regimen A: two cycles of concurrent FP chemotherapy (5-fluorodeoxyuridine 1,000 mg/m2/day, continuous intravenous infusion for four days + cisplatin 75 mg/m2, intravenous infusion on day 1) at four weeks’ interval plus four cycles of adjuvant chemotherapy with the same doses schedule following radiation therapy. Regimen B included: three cycles of concurrent CDDP single agent chemotherapy (cisplatin 100 mg/m2, intravenous infusion on day 1) at three weeks’ interval plus three cycles of adjuvant FP chemotherapy (5-fluorodeoxyuridine 800 mg/m2/day, continuous intravenous infusion for five days + cisplatin 75 mg/m2, intravenous infusion on day 1) at three weeks’ interval following RT. Regimen B was used in 44 patients who were enrolled during the later study period since July, 1996.

All the patients were examined by fiberoptic nasopharyngoscopy on weekly-basis during the RT course. The response was evaluated based by CT or MR images taken within one month of radiotherapy completion. Following completion of the planned treatment schedule including adjuvant chemotherapy, CT, or MR images were repeated every three to four months for the first two years, and every four to six months thereafter.

Results: This study was unique in that the radiation therapy boost technique used for most of the patients in the study was characterized by three-dimensional conformal techniques, while other high dose radiation therapy trials used conventional two-dimensional ways. Resulting side effects by radiation therapy were much lower in incidence and milder in severity. As for chemotherapy regimen, eight patients received FP regimen with poor compliance. However, after changing into a single agent (CDDP) regimen for 44 patients during their radiation therapy, providing a radiosensitizing effect rather than curative cancericidal effect, compliance became much better.

Conclusions: This difference based on the chemotherapy regimen has been first proved in this study, even though this study was not conducted in a prospective randomized fashion. These factors enabled the researchers to achieve high local control rate and survival compared with other trials of concurrent radiochemotherapy.

| newswise
Further information:
http://www.headandneckcancer.org
http://www.sic2004.org

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>